MedTrace Logo

Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer

NCT04740021 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-02-05

No results posted yet for this study

Summary

LP002 is a highly selected recombinant humanized anti-PD-L1 monoclonal antibody. This is a single-arm, multicenter study to evaluate the efficacy and safety of LP002 in combination with chemotherapy in patients with extensive stage samll cell lung cancer.

Conditions

  • Small-cell Lung Cancer

Interventions

DRUG

LP002

10 mg/kg administered as IV infusion on Day 1 of each 21-day cycle.

DRUG

Carboplatin

AUC 5 administered as IV infusion on Day 1 of each 21-day cycle.

DRUG

Etoposide

100 mg/m\^2 administered as IV infusion on Day 1, 2 and 3 of each 21-day cycle.

Sponsors & Collaborators

  • Taizhou HoudeAoke Biomedical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2022-02-01
Completion
2022-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04740021 on ClinicalTrials.gov